All News
Tramadol not effective at chronic pain
The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine.
Read ArticleOptimizing DMARD Therapy in Rheumatoid Arthritis
A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.
Read ArticleNot all difficult-to-treat RA will have rapid radiographic progression
A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.
Associations in Rheumatology (10.3.2025)
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.
Read ArticleActivity Trackers Can Predict RA Flares
People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated.
Read ArticleLung Involvement in Pre-RA
When I see patients with RA-associated ILD, I’m often asked: “Are the lungs and joints really connected?” The answer is yes, and the connection extends further back than some may realize. While RA is defined by inflammation of the joints, extra-articular complications of the lung are well recognized. ILD has often been viewed as a complication of longstanding RA, but it can also appear before joint disease in a subset of patients.
Read ArticleHow Does Your Garden Grow (9.26.2025)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
Read ArticlePolypharmacy Impairs Rheumatoid Arthritis Outcomes
A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs).
Dr. John Cush RheumNow ( View Tweet)
Links:


